title: [New indications for deep brain stimulation: ethical criteria for research and therapy].
abstract: The applications of deep brain stimulation (DBS) are rapidly increasing and now include a large variety of neurological and psychiatric diseases, such as depression, obsessive compulsive disorders, addiction, Alzheimer's disease, anorexia nervosa and rare movement disorders. These new applications confer a huge therapeutic potential in diseases for which often no treatment exists or which are refractory to existing therapies. This spread of applications, however, implies ethical problems in several domains: clinical use, research and presentation in the media and public. Thus, a systematic ethical analysis is needed to inform and guide this process. In this article we identify ethical problems involved in research and clinical use of novel DBS applications, suggest criteria and distinctions for structuring the ethical analysis, and articulate ethical demands for DBS research of novel applications.
authors: Abteilung für Neurodegeneration, Zentrum für Neurologie, Hertie-Institut für Klinische Hirnforschung, Universität Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland, matthis.synofzik@uni-tuebingen.de.
authors: M
authors: M
authors: Synofzik
mesh_terms: D001921:Brain / Q000503:physiopathology; D001927:Brain Diseases / Q000628:therapy*; D046690:Deep Brain Stimulation / Q000009:adverse effects / Q000941:ethics* / Q000592:standards; D004992:Ethics, Medical; D032984:Ethics, Research; D006801:Humans; D007258:Informed Consent; D001523:Mental Disorders / Q000628:therapy*; D057240:Patient Preference; D011379:Prognosis; D018570:Risk Assessment
references: JAMA. 1995 Jan 4;273(1):59-65
references: 7996652
references: J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):102-10
references: 22450620
references: Neurology. 2006 Jun 27;66(12):1811-6
references: 16801642
references: Ann Neurol. 2005 May;57(5):738-41
references: 15852393
references: Neuron. 2005 Mar 3;45(5):651-60
references: 15748841
references: Brain Stimul. 2012 Oct;5(4):653-5
references: 22100456
references: Biotechnol J. 2008 Dec;3(12):1511-20
references: 19072907
references: Eur Addict Res. 2009;15(4):196-201
references: 19622886
references: JAMA. 2010 Feb 24;303(8):775-6
references: 20179289
references: Bioethics. 2008 Jul;22(6):337-45
references: 18522593
references: Lancet. 2013 Jul 27;382(9889):305-6
references: 23890038
references: Neuroimage. 2011 Jan;54 Suppl 1:S247-55
references: 20226259
references: Biol Psychiatry. 2011 Jul 15;70(2):e5-7
references: 21414603
references: JAMA. 2001 Apr 18;285(15):1987-91
references: 11308435
references: Nature. 2007 Aug 2;448(7153):600-3
references: 17671503
references: N Engl J Med. 2013 Feb 14;368(7):610-22
references: 23406026
references: Ann Neurol. 2010 Oct;68(4):521-34
references: 20687206
references: Lancet. 2013 Apr 20;381(9875):1361-1370
references: 23473846
references: Brain Stimul. 2011 Jan;4(1):7-16
references: 21255750
references: Proc Am Thorac Soc. 2007 May;4(2):194-8; discussion 198-9
references: 17494731
references: J Clin Ethics. 2010 Summer;21(2):101-3
references: 20866015
references: Neurol Sci. 2012 Apr;33(2):269-74
references: 21863267
references: J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1152-3
references: 17878197
references: Biol Psychiatry. 2010 Jan 15;67(2):110-6
references: 19914605
references: Neuromodulation. 2012 Jul;15(4):339-49
references: 22624587
references: Ann N Y Acad Sci. 2013 Apr;1282:119-28
references: 23227826
references: Tremor Other Hyperkinet Mov (N Y). 2012;2:
references: 23440258